Q-omics provides the consensus-scored CTNNA1 profile across patient tissues and cancer cell-line models. CTNNA1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CTNNA1 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, CTNNA1 protein abundance shows 27,324 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, LIHC, and HNSC as cancer lineages where CTNNA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTNNA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTNNA1 survival associations across molecular data types. CTNNA1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTNNA1 RNA expression–survival associations across cancer types. High CTNNA1 expression shows unfavorable associations in HNSC, CESC, LGG, PAAD and LUAD, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CTNNA1 RNA expression.
This table summarizes CTNNA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CTNNA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTNNA1 shows lower tumor expression in KICH and LUSC and higher tumor expression in LIHC, BRCA, CHOL and KIRP. The LIHC box plot shows higher CTNNA1 RNA expression in tumor versus normal tissue (log2 FC = +1.350, t-test p < 0.001).
This table shows molecular features associated with CTNNA1 in patient tissues and cancer cell lines. In patient samples, CTNNA1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, CTNNA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
